NO20070973L - Antagonisering av interleukin-21 reseptoraktivitet - Google Patents
Antagonisering av interleukin-21 reseptoraktivitetInfo
- Publication number
- NO20070973L NO20070973L NO20070973A NO20070973A NO20070973L NO 20070973 L NO20070973 L NO 20070973L NO 20070973 A NO20070973 A NO 20070973A NO 20070973 A NO20070973 A NO 20070973A NO 20070973 L NO20070973 L NO 20070973L
- Authority
- NO
- Norway
- Prior art keywords
- interleukin
- antagonization
- receptor activity
- receptor
- antagonists
- Prior art date
Links
- 108010017411 Interleukin-21 Receptors Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 102000004527 Interleukin-21 Receptors Human genes 0.000 title 1
- 102100030704 Interleukin-21 Human genes 0.000 abstract 4
- 108010074108 interleukin-21 Proteins 0.000 abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 102100030699 Interleukin-21 receptor Human genes 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 abstract 2
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59908604P | 2004-08-05 | 2004-08-05 | |
US63917604P | 2004-12-23 | 2004-12-23 | |
PCT/US2005/027912 WO2006135385A2 (en) | 2004-08-05 | 2005-08-05 | Antagonizing interleukin-21 receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070973L true NO20070973L (no) | 2007-05-04 |
Family
ID=37309615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070973A NO20070973L (no) | 2004-08-05 | 2007-02-21 | Antagonisering av interleukin-21 reseptoraktivitet |
Country Status (16)
Country | Link |
---|---|
US (2) | US20060039902A1 (es) |
EP (1) | EP1773394A2 (es) |
JP (1) | JP2008508885A (es) |
KR (1) | KR20070057789A (es) |
AR (1) | AR051071A1 (es) |
AU (1) | AU2005332996A1 (es) |
BR (1) | BRPI0514138A (es) |
CA (1) | CA2574848A1 (es) |
CR (1) | CR8891A (es) |
EC (1) | ECSP077226A (es) |
IL (1) | IL181044A0 (es) |
MX (1) | MX2007001509A (es) |
NO (1) | NO20070973L (es) |
RU (1) | RU2007102287A (es) |
TW (1) | TW200608995A (es) |
WO (1) | WO2006135385A2 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110075507A1 (en) * | 1997-10-24 | 2011-03-31 | Revalesio Corporation | Diffuser/emulsifier |
US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US7314623B2 (en) | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
JP4914209B2 (ja) | 2003-03-14 | 2012-04-11 | ワイス | ヒトil−21受容体に対する抗体および該抗体の使用 |
US20060159655A1 (en) * | 2003-03-21 | 2006-07-20 | Wyeth | Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor |
JP2008532493A (ja) | 2005-02-14 | 2008-08-21 | ワイス | Il−17fとil−17rとの間の相互作用の特性解析 |
AR052289A1 (es) * | 2005-02-14 | 2007-03-07 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f y sus usos |
GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
BRPI0609079A2 (pt) | 2005-04-18 | 2010-11-16 | Novo Nordisk As | peptìdeo, composição farmacêutica, método para o tratamento de cáncer, uso de um peptìdeo construto de ácido nucleico, vetor, hospedeiro, e, anticorpo |
RU2446826C2 (ru) * | 2005-10-14 | 2012-04-10 | Фукуока Юниверсити | Агенты для подавления повреждения трансплантированных островков после трансплантации островков |
AR058135A1 (es) * | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
AR057941A1 (es) * | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
EP2567973B1 (en) * | 2005-11-28 | 2014-05-14 | Zymogenetics, Inc. | IL-21 antagonists |
JP5033643B2 (ja) * | 2006-01-27 | 2012-09-26 | 学校法人慶應義塾 | 脈絡膜血管新生を伴う疾患の治療剤 |
CA2648644C (en) * | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
EP2086668B1 (en) * | 2006-10-25 | 2016-11-16 | Revalesio Corporation | Mixing device and method |
WO2008052145A2 (en) | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
US8609148B2 (en) * | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
AU2007336184A1 (en) * | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the IL-21 receptor |
RU2450829C2 (ru) * | 2007-01-23 | 2012-05-20 | Синсу Юниверсити | Ингибитор хронического отторжения |
TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
US9745567B2 (en) * | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US20090263495A1 (en) * | 2007-10-25 | 2009-10-22 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US10125359B2 (en) * | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US20100009008A1 (en) * | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US20100303917A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for treating cystic fibrosis |
WO2010062628A1 (en) * | 2008-10-27 | 2010-06-03 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US20100015235A1 (en) * | 2008-04-28 | 2010-01-21 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US20100303871A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
CN101909869B (zh) * | 2007-10-25 | 2014-12-17 | 利发利希奥公司 | 抑菌或杀菌的组合物和方法 |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
US20100029764A1 (en) * | 2007-10-25 | 2010-02-04 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
US20100303918A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
CA2910933C (en) | 2007-12-07 | 2017-04-11 | Zymogenetics, Inc. | Anti-human il-21 monoclonal antibodies |
US20110014624A1 (en) * | 2008-03-12 | 2011-01-20 | Wyeth Llc | Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins |
WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
JP5901291B2 (ja) * | 2008-05-01 | 2016-04-06 | リバルシオ コーポレイション | 消化器障害を治療するための組成物および方法 |
EP2296689A1 (en) * | 2008-05-23 | 2011-03-23 | Wyeth LLC | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
AR071885A1 (es) * | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
CN102256623A (zh) * | 2008-06-05 | 2011-11-23 | 独立行政法人国立癌症研究中心 | 神经浸润抑制剂 |
CA2739357A1 (en) * | 2008-09-23 | 2010-04-08 | Wyeth Llc | Methods for predicting production of activating signals by cross-linked binding proteins |
HUE035208T2 (hu) * | 2008-10-08 | 2018-05-02 | Cambridge Entpr Ltd | Eljárás és készítmény sclerosis multiplexet követõ másodlagos autoimmun betegség diagnosztizálására és kezelésére |
US20100098659A1 (en) * | 2008-10-22 | 2010-04-22 | Revalesio Corporation | Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
EP2467160B1 (en) * | 2009-08-17 | 2016-11-16 | A & G Pharmaceutical, Inc. | Materials and methods for the development of an antigen-specific immune non-responsiveness state |
KR101004363B1 (ko) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 TNF-α와 IL-21 이중 길항제 |
US9464329B2 (en) | 2010-03-26 | 2016-10-11 | Monsanto Technology Llc | Portable systems and methods for amplifying nucleotides and detecting nucleotide sequences |
AU2011249856B2 (en) | 2010-05-07 | 2015-11-26 | Revalesio Corporation | Compositions and methods for enhancing physiological performance and recovery time |
PL2578231T3 (pl) | 2010-05-28 | 2023-01-16 | Chugai Seiyaku Kabushiki Kaisha | Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t |
US20130224109A1 (en) * | 2010-07-20 | 2013-08-29 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods featuring il-6 and il-21 antagonists |
JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
ES2778053T3 (es) | 2011-01-18 | 2020-08-07 | Bioniz Llc | Composiciones para modular la actividad de la citocina gamma-c |
KR20130011056A (ko) * | 2011-07-20 | 2013-01-30 | 주식회사에이앤알쎄라퓨틱스 | 염증표적 수용체 및 염증 질환 치료용 약물 운반체 |
EP2565881B1 (en) * | 2011-08-30 | 2018-06-13 | ABB Schweiz AG | Dry-type transformer |
WO2013096732A2 (en) * | 2011-12-23 | 2013-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating or preventing viral diseases by blocking interleukin-21 |
WO2014172606A1 (en) * | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
DK3128997T3 (da) | 2014-04-08 | 2020-08-24 | Boston Pharmaceuticals Inc | Bindingmolekyler specifikke for il-21 og anvendelser deraf |
US10662240B2 (en) * | 2014-12-19 | 2020-05-26 | Mabtech Ab | Composition, kit and method for inhibition of IL-21 mediated activation of human cells |
EP3359556B1 (en) | 2015-10-09 | 2021-05-26 | Bioniz, LLC | Modulating gamma - c -cytokine activity |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
WO2018013585A1 (en) * | 2016-07-12 | 2018-01-18 | Flagship Pioneering, Inc. | Methods and compositions for modulating thymic function |
US10875828B2 (en) * | 2016-08-05 | 2020-12-29 | The Regents Of The University Of California | Mithrene and methods of fabrication of mithrene |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
CN110124029B (zh) * | 2019-04-19 | 2023-08-11 | 中山大学附属第六医院 | Il-6r抗体及羊水干细胞在制备用于治疗nec的药物中的应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US425871A (en) * | 1890-04-15 | Half to james l | ||
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
CN1300173C (zh) * | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
ATE456654T1 (de) * | 2000-04-05 | 2010-02-15 | Zymogenetics Inc | Löslicher zytokinrezeptor zalpfa11 |
ES2629395T3 (es) * | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Métodos y composiciones para modular la actividad de la interleucina-21 |
AU2003230834A1 (en) * | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
JP4914209B2 (ja) * | 2003-03-14 | 2012-04-11 | ワイス | ヒトil−21受容体に対する抗体および該抗体の使用 |
US20060159655A1 (en) * | 2003-03-21 | 2006-07-20 | Wyeth | Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor |
US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2005
- 2005-08-05 EP EP05857905A patent/EP1773394A2/en not_active Withdrawn
- 2005-08-05 US US11/197,488 patent/US20060039902A1/en not_active Abandoned
- 2005-08-05 KR KR1020077002877A patent/KR20070057789A/ko not_active Application Discontinuation
- 2005-08-05 CA CA002574848A patent/CA2574848A1/en not_active Abandoned
- 2005-08-05 BR BRPI0514138-9A patent/BRPI0514138A/pt not_active IP Right Cessation
- 2005-08-05 AR ARP050103287A patent/AR051071A1/es unknown
- 2005-08-05 AU AU2005332996A patent/AU2005332996A1/en not_active Abandoned
- 2005-08-05 JP JP2007525033A patent/JP2008508885A/ja not_active Withdrawn
- 2005-08-05 MX MX2007001509A patent/MX2007001509A/es not_active Application Discontinuation
- 2005-08-05 RU RU2007102287/13A patent/RU2007102287A/ru not_active Application Discontinuation
- 2005-08-05 WO PCT/US2005/027912 patent/WO2006135385A2/en active Application Filing
- 2005-08-08 TW TW094126735A patent/TW200608995A/zh unknown
-
2007
- 2007-01-29 IL IL181044A patent/IL181044A0/en unknown
- 2007-02-01 CR CR8891A patent/CR8891A/es not_active Application Discontinuation
- 2007-02-05 EC EC2007007226A patent/ECSP077226A/es unknown
- 2007-02-21 NO NO20070973A patent/NO20070973L/no not_active Application Discontinuation
- 2007-11-29 US US11/947,425 patent/US20080241098A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0514138A (pt) | 2008-05-27 |
EP1773394A2 (en) | 2007-04-18 |
WO2006135385A2 (en) | 2006-12-21 |
AU2005332996A1 (en) | 2006-12-21 |
CA2574848A1 (en) | 2006-12-21 |
ECSP077226A (es) | 2007-03-29 |
AR051071A1 (es) | 2006-12-20 |
MX2007001509A (es) | 2007-03-27 |
TW200608995A (en) | 2006-03-16 |
US20060039902A1 (en) | 2006-02-23 |
IL181044A0 (en) | 2007-07-04 |
CR8891A (es) | 2007-08-28 |
JP2008508885A (ja) | 2008-03-27 |
RU2007102287A (ru) | 2008-09-10 |
US20080241098A1 (en) | 2008-10-02 |
WO2006135385A3 (en) | 2007-02-22 |
KR20070057789A (ko) | 2007-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070973L (no) | Antagonisering av interleukin-21 reseptoraktivitet | |
WO2010106436A3 (en) | Novel anti-inflammatory agents | |
NO20054343L (no) | Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor | |
MY144906A (en) | Human antibodies against il13 and therapeutic uses | |
WO2005063766A3 (en) | Bicyclic heterocyclic p-38 kinase inhibitors | |
MA32481B1 (fr) | Compositions et procédés d'utilisation pour des anticorps thérapeutiques | |
WO2005000298A3 (en) | 5-membered heterocycle-based p-38 inhibitors | |
WO2009007849A3 (en) | Il-23 receptor antagonists and uses thereof | |
TW200738660A (en) | Piperidinyl derivatives as modulators of chemokine receptor activity | |
JP2009531059A5 (es) | ||
WO2004108133A3 (en) | Modulators of vr1 receptor | |
WO2006069805A3 (en) | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment | |
WO2002088079A3 (en) | DUAL INHIBITORS OF PDE 7 AND PDE 4 | |
WO2006001958A3 (en) | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | |
WO2006003388A3 (en) | Compositions and methods for treating inflammatory disorders | |
WO2008071605A3 (en) | Methods of treating inflammatory diseases | |
WO2006135839A3 (en) | Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor | |
MX2008013597A (es) | Antagonistas del ligado 13 de quimiocina de motivo cxc (cxcl13) y su uso para el tratamiento de enfermedades inflamatorias. | |
WO2010112458A8 (en) | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit | |
WO2004010942A3 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
CL2003002678A1 (es) | Compuestos derivados de piperidina, moduladores de la actividad del receptor ccr5; procedimiento de preparacion; composicion farmaceutica, y su uso en el tratamiento de enfermedades inmunologicas, inflamatorias, asma, artritis reumatoidea y ateroescl | |
WO2006135694A3 (en) | Uii-modulating compounds and their use | |
DE60044247D1 (de) | Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung | |
MX2007001876A (es) | Antagonistas de antigeno muy tardio-4. | |
UY29572A1 (es) | Derivados n-amida de 8-azabiciclo(3.2.1)oct-3-ilo como antagonistas del ccr1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |